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The molecular signatures of epigenetic regulation and chromatin architecture are
emerging as pivotal regulators of mitochondrial function. Recent studies unveiled a
complex intersection among environmental factors, epigenetic signals, andmitochondrial
metabolism, ultimately leading to alterations of vascular phenotype and increased
cardiovascular risk. Changing environmental conditions over the lifetime induce covalent
and post-translational chemical modification of the chromatin template which sensitize
the genome to establish new transcriptional programs and, hence, diverse functional
states. On the other hand, metabolic alterations occurring in mitochondria affect the
availability of substrates for chromatin-modifying enzymes, thus leading to maladaptive
epigenetic signatures altering chromatin accessibility and gene transcription. Indeed,
several components of the epigenetic machinery require intermediates of cellular
metabolism (ATP, AcCoA, NADH, α-ketoglutarate) for enzymatic function. In the present
review, we describe the emerging role of epigenetic modifications as fine tuners of gene
transcription in mitochondrial dysfunction and vascular disease. Specifically, the following
aspects are described in detail: (i) mitochondria and vascular function, (ii) mitochondrial
ROS, (iii) epigenetic regulation of mitochondrial function; (iv) the role of mitochondrial
metabolites as key effectors for chromatin-modifying enzymes; (v) epigenetic therapies.
Understanding epigenetic routes may pave the way for new approaches to develop
personalized therapies to prevent mitochondrial insufficiency and its complications.
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MITOCHONDRIA AND VASCULAR FUNCTION
Mitochondria, defined as semi-autonomous, membrane-bound organelle localized in the
cytoplasm of eukaryotic cells, are emerging as a pivotal player in health, disease, and aging
by regulating reactive oxygen species (ROS) production and contributing to retrograde redox
signalling from the organelle to the cytosol and nucleus (Figure 1) (1, 2). Mitochondria play
an important role in the overall cellular network formed by metabolic signalling and epigenetic
pathways. Indeed, mitochondria drive catabolic and anabolic reactions supplying energy and
metabolites with biosynthetic and signalling roles (3). They also maintain a bidirectional signalling
crosstalk with the nucleus that generates reciprocal activation-repression patterns of gene
expression (3–5). Finally, mitochondria can determine apoptotic and necrotic cell death mediated
by Ca2+ overload and opening of the permeability transition pore (PTP) (6, 7).
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Under physiological conditions, mitochondria undergo
highly coordinated cycles of fission (division of a single organelle
into two or more independent structures) or fusion (the
opposing reaction) (8). Fission and fusion are active processes
which require many specialized proteins, including mechanical
enzymes that physically alter mitochondrial membranes,
and adaptor proteins that regulate the interaction of these
mechanical proteins with organelles. The balance between these
two processes regulates the overall morphology of mitochondria
within any given cell (8–10). The content of mitochondria
in the cytoplasm of eukaryotic cells depend on two major
processes known as mitochondrial biogenesis and mitophagy
(11). Mitochondrial biogenesis is an intricate and not fully
understood process which leads to an increased mitochondrial
mass mainly via replication of mitochondrial DNA (mtDNA)
and expression of nuclear and mitochondrial genes (12).
PGC-1α (Peroxisome proliferator-activated receptor gamma
coactivator−1α) plays a prominent role in mitochondrial
biogenesis by activating the nuclear respiratory factor (Nrf)-1
FIGURE 1 | Main features of healthy and diseased mitochondria, and implications for cardiovascular disease.
and −2 to promote the expression nuclear genes. PGC-1α
also activates transcription factors A and B which regulate
the expression of mitochondrial genes (13, 14). Following
mitochondrial damage, the organelles are being selectively
degraded according to a well-known biological process called
mitophagy, which promotes organelle turnover while preventing
accumulation of dysfunctional mitochondria (Figure 1) (11).
In addition to the selective removal of damaged mitochondria,
mitophagy is also required to adjust mitochondrial numbers to
changing cellular metabolic needs, for steady-state mitochondrial
turnover, and during certain cellular developmental stages, such
as during cellular differentiation of red blood cells (10).
Mitochondrial content may vary based on the cell type and
its function. For example, in endothelial cells mitochondria
occupy around 6% of cytoplasm whereas in cardiomyocytes
this reaches 32% (15). Notably, the blood brain barrier which
consist of highly active endothelial cells has higher mitochondrial
content as compared with endothelial cells present in capillary
beds (15). Mitochondria play a pivotal role in endothelial
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cells. Several biological processes including mitochondrial
biogenesis, fission and fusion as well as mitophagy, have shown
to clearly affect endothelial cell function and metabolism. Several
stimuli including hypoxia, calorie restriction or exercise induce
mitochondrial biogenesis in endothelial cells by increasing the
expression of the peroxisome proliferator-activated receptor-γ
coactivator-1α (PGC-1α). Induction of PGC-1α is associated
with a favorable transcriptional profile which protects endothelial
cells from oxidative damage and apoptosis (16). In line with this
notion, endothelial-specific overexpression of PGC-1α protects
against angiotensin II–induced hypertension (17). By contrast,
loss of endothelial PGC-1α impairs endothelial NO bioactivity
eventually leading to endothelial dysfunction (18). Alterations
of mitochondrial dynamics also contribute to endothelial cell
phenotype. Endothelial cells from patients with diabetes display
mitochondrial fragmentation and increased expression of
fission-1 protein (Fis1) and dynamin-related protein-1 (Drp1).
Of note, in vitro experiments showed that gene silencing Fis1
or Drp1 expression blunted hyperglycemia-induced alterations
in mitochondrial networks, ROS production, endothelial
nitric oxide synthase activation, and cGMP production (19).
Alterations of mitophagy as the result of disturbed Ucp2/PTEN
signaling were also associated with inadequate mitochondrial
biosynthesis and increased apoptosis in endothelium (20).
Altered mitochondrial clearance may also contribute to age-
dependent endothelial dysfunction. Indeed, senescent cells
display altered mitochondrial dynamics and loss of membrane
potential (21). Interestingly enough, overexpression of proteins
involved in the autophagosome formation (ATG5 and ATG12)
was associated with improved mitochondrial performance,
as evidenced by higher membrane potential, increased ATP
production, and decreased damage to mtDNA (22, 23).
MITOCHONDRIAL ROS
Although several cytosolic enzymes (i.e., NADPH,
cyclooxygenases, and xanthine oxidase) are implicated in
redox balance, ROS generated from mitochondrial oxidative
phosphorylation represent the most important source of
oxidative stress in vascular cells (i.e., endothelial cells) (24, 25).
Mitochondrial ROS are responsible for peroxidation of
polyunsaturated fatty acids (PUFAs) present in the cellular
membrane as well as DNA (causing single and double strand
breaks) and protein damage via oxidation of sulfhydryl and
aldehyde groups, protein-protein interactions and fragmentation
(26). In addition, damage of mtDNA may lead to decreased
expression of electron transport chain components or expression
of defective components that produce more ROS, thus creating a
detrimental vicious cycle. mtDNA disruption also correlates with
the extent of atherosclerosis in mouse models and human tissues.
Despite the highly efficient chemical reduction of O2 through
cytochrome c oxidase, mitochondria still generate significant
levels of ROS (27). Cellular and mitochondrial physiological
levels of ROS are reached when production and scavenging are
balanced (28). Mitochondrial dysfunction is believed to play an
important role in a variety of diseases including diabetes, obesity,
dyslipidaemia, hypertension, arrhythmias, and sudden cardiac
death (29–31).
In the setting of cardiovascular risk factors, namely
hyperglycemia, mitochondrial ROS can be regarded as an
upstream biochemical event responsible for the activation of
pro-inflammatory pathways (i.e., NF-kB), protein kinase C
as well as advanced glycation end products (AGEs) (32). An
increasing body of evidence has contributed to unveil different
sources of mitochondrial ROS in endothelial cells. Studies
in isolated mitochondria have shown that superoxide anion
formation at complexes I and III accounts for 0.1-2% of the
total (33). In addition to complexes I and III, the nicotinamide
adenine dinucleotide phosphate oxidase (NOX) 4—a ROS-
generating enzyme involved in endothelial cell senescence,
migration, angiogenesis, and adaptive responses to hypoxia—is
highly expressed in vascular cells and has been localized to
mitochondria (34). Moreover, the monoamine oxidase (MAO)
family of enzymes—which is found in the outer mitochondrial
membrane—generates hydrogen peroxide (H2O2) during
catabolism of catecholamines and has been implicated in
maladaptive cellular hypertrophy and apoptosis (35). MAO-A-
induced ROS are involved in serotonin-induced vasoconstriction
in vascular smooth muscle cells (36). Although endothelial
cells are known to express MAO, its importance for endothelial
function is poorly understood (37). The mitochondrial adaptor
protein p66Shc was recently shown to be causally involved in
mitochondrial ROS generation and cellular death. In conditions
of cellular stress, p66Shc is phosphorylated at ser36 by protein
kinase C beta2 (PKCβ2) and translocates to the mitochondria
where it oxidizes cytochrome c, leading to accumulation of H2O2,
PTP opening, and release of solutes and proapoptotic signals
(38). The causal role of p66Shc in vascular disease is supported
by the notion that its genetic deletion or gene silencing prevents
age and hyperglycemia-induced endothelial dysfunction in mice
(39–41). The prolyl-isomerase 1 (Pin1), which regulates p66Shc
translocation to the mitochondria, has also shown to be causally
implicated in the regulation of mitochondrial oxidative stress
and integrity in experimental models of diabetes (42, 43). The
mitochondrial ATP-sensitive potassium channel (mitoKATP) was
also recently discovered as a potential source of mitochondrial
ROS in cardiac myocytes (44). Although the exact mechanism of
action remains elusive, mitoKATP seems to act as an uncoupling
agent by reducing membrane potential and mitochondrial
calcium. Pharmacological inhibition of mitoKATP was found to
improve endothelial function and to prevent ischemia-induced
cellular apoptosis (44). Several antioxidant enzymes play a pivotal
role in maintaining redox balance in mitochondria. Manganese
superoxide dismutase (MnSOD) represents one of the first line
defense against accumulation of mitochondrial superoxide.
MnSOD is located in the mitochondrial matrix and catalyzes
the conversion of superoxide anion to hydrogen peroxide
(45). Loss of MnSOD in mice leads to impaired endothelium-
dependent vasodilation, suggesting its role in regulating vascular
function. In addition, ApoE−/− MnSOD+/− mice display
early mtDNA damage and accelerated atherosclerosis when
compared to control animals (46). Levels of H2O2 are regulated
by glutathione peroxidase-1, thioredoxin-2, peroxiridoxin-3,
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FIGURE 2 | Environmental factors, chromatin modifications, and mitochondrial damage. Environmental factors lead to specific epigenetic signatures as well as to
alterations of mitochondrial intermediate metabolites (i.e., acetyl-CoA, FAD+, NAD+). These two processes influence each other, thus leading to a vicious cycle
responsible for adverse chromatin modifications, maladaptive transcriptional programs, and vascular dysfunction. ROS, reactive oxygen species.
and glutaredoxin-2 (47). As noted, increased expression of
these enzymes is signaled by AMPK and PGC-1α in response to
H2O2 and other free radicals in endothelial cells (48). Studies
in experimental models have shown that reduced expression of
mitochondrial antioxidant enzymes can induce mitochondrial
damage, endothelial dysfunction, and atherogenesis (45, 46).
Conversely, overexpression of these proteins is protective against
the development of vascular disease (49).
Although the role of mitochondrial ROS in vascular
damage is well-established, only few studies have explored
the specific contribution of mitochondria-derived ROS
in the pathophysiology of endothelial dysfunction in
humans. Mitochondrial ROS production and membrane
hyperpolarization are significantly altered in visceral fat arteries
and peripheral blood mononuclear cells isolated from patients
with obesity and type 2 diabetes (50, 51). Furthermore, impaired
endothelium-dependent vasodilation in freshly isolated arterioles
from diabetic individuals is reversed by mild membrane
depolarization or mitochondria-targeted antioxidants (50).
EPIGENETIC REGULATION OF
MITOCHONDRIAL FUNCTION
Recent evidence indicates that epigenetic changes, defined as
plastic modifications of DNA/histone complexes, are heavily
implicated in the regulation of mitochondrial and vascular
function (52, 53). Studies conducted over the last few years
have unmasked a complex intersection among environmental
factors, mitochondrial metabolism, epigenetic signals and
transcriptional programs (54, 55). Epigenetic changes acquired
during the life time may derail the expression of genes involved
in mitochondrial homeostasis (52). On the other hand, metabolic
alterations occurring in mitochondria may affect the availability
of substrates for chromatin-modifying enzymes, thus leading
to maladaptive epigenetic signatures altering chromatin
accessibility and, hence, gene transcription (Figure 2) (54).
Indeed, the availability of some intermediate mitochondrial
metabolites (ATP, AcCoA, NADH, α-ketoglutarate) has shown
to foster different patterns of epigenetic modifications. For
examples, iron, α-ketoglutarate (α-KG) and O2 are needed
both for histone demethylation—catalysed by iron-containing
jumonji-domain (jmjC) demethylases (56)—as well as for DNA
demethylation of 5-methylcytosine—catalysed by the ten-eleven
translocation family of dioxygenases (TET) (57). Therefore,
mitochondrial sensitivity determined by environmental
factors and lifestyle changes (sedentarism, physical activity,
overnutrition, balanced nutrition) will favor, or prevent, the
effects of metabolic disorders.
CLASSIFICATION OF EPIGENETIC
CHANGES
Epigenetic mechanisms can be divided into three main
categories: (i) chemical modifications of DNA (i.e., methylation);
(ii) post-translational modifications of histone tails; (iii)
regulation of gene expression by non-coding RNAs [i.e.,
microRNAs, long non-coding RNAs (lncRNAs)] (58). In
the present review, we will focus on the modifications of
DNA/histone complexes and their impact on mitochondrial
integrity and functionality.
DNA Methylation
Methylation of DNA mainly takes place at the level of CpG
regions of gene promoters through the attachment of methyl
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group (CH3) from S-adenosyl methionine (SAM) to the
C5 position in the cytosine-paired-with-guanine (CpG)
dinucleotide sequences (59). CpG sequences are generally
located into promoter regions of genes, however, they can also
be located within gene bodies (58). Promoter methylation
is generally associated with transcriptional repression,
while gene body methylation is associated with enhanced
transcription (60). Promoter methylation hampers gene
expression mainly via two mechanisms: (i) by fostering
transcriptional silencing, or (ii) by preventing the recruitment
of transcription factors (61). Specifically, methylated cytosines
are recognized by DNA methyl-binding proteins (MBPs) that
repress gene transcription by preventing the interaction of
transcription factors with the promoter (62). Alternatively,
DNA methylation may recruit specific proteins that may
also favor the recruitment of enzymes catalysing histone
posttranslational modifications (PTMs) with subsequent gene
repression (63, 64).
DNA methylation is a relatively stable epigenetic signature,
it can be tissue-specific and, most importantly, it can be
transmitted to the offspring, a phenomenon known as “epigenetic
inheritance” (65). Different families of enzymes, known as
methyltransferases (DNMTs), are involved in the regulation of
DNA methylation: DNMT1 is responsible for the maintenance
of methylation patterns in the genome by replicating the hemi-
methylated CpG sites (66), whereas Dnmt3a/b are considered
de novo methyltransferases (67). Methylation of DNA is a
dynamic and reversible process governed by methyl-writing and
-erasing enzymes (58). DNA demethylation can be achieved
by either passive or active mechanisms (58). Active DNA
demethylation consists in the removal of the methyl group
by breaking a carbon–carbon bond. DNA demethylation may
follow two main pathways: the first is dependent on cytosine
deamination (AID, APOBEC3G, FTO) while the second is
dependent on the oxidation of methylated cytosines (68). This
latter reaction is catalysed by members of the Ten-eleven
translocation (TET) proteins family (TET1-3) that convert 5-
methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC)
(69, 70). TET1 is mostly found in embryonic stem cells,
whereas TET2 and TET3 are ubiquitously expressed. TET1-
3 proteins could further oxidize 5hmC to 5-formylcytosine
(5fC) and 5-carboxylcytosine (5caC) that are recognized and
excised by the thymine DNA glycosylase (TDG) via the base
excision repair pathway (70, 71). By contrast, passive DNA
demethylation is the result of DNMT1 inhibition during DNA
replication (69).
Histone Modifications
DNA is packaged into repeating units called nucleosomes
by wrapping around multimeric histone proteins. When
nucleosomes are organized into tightly packed bundles
(heterochromatin), the transcriptional machinery is
hampered by a reduction of chromatin accessibility.
Conversely, when chromatin is relaxed (euchromatin),
DNA is more accessible to transcription factors, and gene
transcription may occur (72). Histones are amenable to
many posttranslational modifications (PTMs), which include
methylation, acetylation, ubiquitination, phosphorylation,
SUMOylation, GlcNAcylation, carbonylation, and ADP-
ribosylation (73, 74). Of interest, these modifications may
cluster in different patterns to regulate chromatin accessibility
(59, 72, 75). Albeit the biological significance of many
PTMs remains to be elucidated, considerable advances have
been made in the understanding of lysine acetylation and
methylation (74).
Histone acetylation, characterized by the addition of positively
charged acetyl groups to amino acid residues at the level
of histone tails, reduces the affinity of histones for DNA
thus increasing chromatin accessibility (76). Acetylation occurs
mainly on lysine residues on histones H3 and H4; this mark
mainly associates with activation of transcription by enhancing
chromatin accessibility (77). In this context, bromodomain
and extra-terminal proteins recognize histone acetylation marks
and initiate the assembly of the transcriptional machinery
(78). By contrast, non-acetylated histones have been observed
in transcriptionally silent genes where chromatin is compact
(79). Acetylation is modulated by histone acetyltransferases
(HATs) and histone deacetylases (HDACs) which are involved
in addition or removal of an acetyl group, respectively (80).
This modification is driven by recognition and binding of
transcription factors able to recruit one of a growing family
of HATs, namely CBP/p300, MYST, and GNAT (59, 73). HATs
catalyse the addition of two-carbon acetyl groups to lysine
residues from acetyl-CoA thus leading to gene expression (81).
On the other hand, removal of acetyl groups from histone
residues by HDACs represses gene transcription (82, 83).
Several HDACs have been reported in humans, and they are
subdivided into four classes (Class I, IIa, IIb, III, and IV)
(84, 85).
In contrast to lysine acetylation, which enhances gene
expression, histone methylation may result in different
chromatin states according to the methylated residue and
the number of added methyl groups (79). Histone methylation
is defined as the transfer of methyl group from S-adenosyl-
L-methionine to lysine or arginine residues of histone
proteins by histone methyltransferases (HMTs) (86). Histone
methyltransferases (HMTs) have higher specificity as compared
to HATs (87) and include several families of enzymes (EZH,
SETD, PRDM, PRMT, METTL, and MLL) (88). Recent evidence
indicates that a fine balance between histone methylation
and demethylation plays a pivotal role in the regulation of
chromatin accessibility.
Several lysine demethylases specific for diverse histone lysine
residues have been identified (89). HDMs include members
of UTX/Y, JARID1, JMJD, LSD, PHF, and FBXL enzyme
families (88).
Interestingly, modifications of histones may reciprocally
influence or eventually affect DNA methylation (74). In
this regard, recent evidence suggests that DNA methylase
(DNMTs), histone methyltransferase (HMTs), and histone
acetyltransferase (HATs) are closely interconnected to
regulate chromatin remodeling under specific stimuli (90).
A well-described crosstalk between DNA methylation and
histone H3K9 methylation, mediated by the heterochromatin
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protein 1 (HP1), represents a valid example of how histone
modifications may facilitate the recruitment of enzymes
(DNTM3a/b) involved in DNA methylation (91). Another
example is methyl-CpG binding protein 2 (MECP2),
which recruits the histone methyltransferase SUV39H1
only after binding methylated DNA (92, 93). Therefore,




Increasing evidence suggests that aberrant mitochondrial DNA
(mtDNA) modification play an important role in disease
development and progression (94). Since the vast majority of
mitochondrial proteins are encoded in the nuclear genome,
appropriate communication between the nuclear, cytoplasmic
and mitochondrial compartments is essential for maintaining
proper mitochondrial function. The mitochondrial genome
consists of roughly 1,500 genes distributed across the maternal
mtDNA and nuclear DNA (nDNA) (95). Human mtDNA is
a 16.5-kb circular double-stranded DNA containing a heavy
(H) and a light (L) strand located in the mitochondrial matrix
(96, 97). mtDNA forms an mtDNA–protein complex, known
as nucleoid, with a range of proteins including prohibitins,
ATPase family AAA domain-containing protein 3 (ATAD3),
mitochondrial transcription factor A (TFAM) and POLG (DNA
polymerase gamma, catalytic subunit) (98, 99). In contrast to
nDNA, human mtDNA is maternally inherited, is intronless,
and lacks histones (100). It contains 37 genes encoding 13
subunit of the oxidative phosphorylation (OXPHOS) complexes
I, III, IV, and V; two rRNAs; and 22 tRNAs (2). All other
mitochondrial proteins, including those required for mtDNA
replication and transcription, are encoded in the nucleus and
translocated to the mitochondria using specialized import
systems which often involve N-terminal mitochondrial targeting
sequences (101).
Emerging evidence suggests that mtDNA may also be
regulated at the epigenetic level in the form of mtDNA
methylation (2). While nDNA methylation is a well-established
feature, mtDNA methylation has been a matter of debate
(94, 102). The prevailing opinion was that mtDNA cannot be
methylated for two main reasons: (i) methylase cannot access
mitochondria, and (ii) mtDNA is not complexed with histones
(103). Only recently, mtDNA has been reported to contain
5-methylcytosine (5mC) as well as 5-hydroxymethylcytosine
(5hmC) at CpG dinucleotides. In 2011, Shock et al. have
identified a mitochondrially targeted DNMT1 transcript variant
(mtDNMT1) that uses an upstream alternative translation
start site leading to the inclusion of a mitochondrial targeting
sequence (101). mtDNMT1 binds to the mitochondrial
genome in a manner proportional to the density of CpG
dinucleotides. Of note, cytosine methylation in mtDNA may
play different role. Indeed, mtDNA methylation represses
gene expression from the light-strand promoter. However,
increased or no change in transcription of genes from the
heavy-strand promoter raises the possibility of a different
mode of action (104). This DNMT1 variant is upregulated
by the hypoxia-responsive transcription factors peroxisome
proliferator-activated receptor gamma coactivator 1 alpha
(PGC1a) and nuclear respiratory factor 1 (NRF1) suggesting a
regulatory role of mtDNMT1 during vascular oxidative stress
(Figure 3) (101).
Besides mtDNMT1, no other specific mitochondrially
targeted isoforms of enzymes involved in DNA methylation
or hydroxymethylation are known (100). Nevertheless, other
enzymes, namely DNMT3A/B and ten–eleven translocation
(TET) 1 and 2, have been detected in the mitochondrial protein
fraction (105). Interestingly, the presence of these enzymes in
the mitochondria seems to be tissue specific. Indeed, inside the
mitochondria of ‘excitable tissues’ (heart, skeletal muscle, and
neurons) only DNMT3A but not DNMT3b has been detected
(106). Furthermore, epigenetic modifications of mtDNA can
modulate the activity of nDNA, and vice versa (107). Under
conditions of oxidative stress, such as exposure to hypoxia or
ethanol, DNMT1 is upregulated and suppresses the expression of
ND6 (101), while ND1 is upregulated. Although the significance
of opposite ND1 and ND6 regulation is poorly understood,
a proposed mechanism involves the interaction of MTERF1
(mitochondrial terminator factor 1) with 5-methylcytosine in the
CpG dinucleotides and/or its interaction with mtDNA-bound
mtDNMT1 (94).
An interesting study by Byun et al. showed a higher
mtDNA methylation level in workers highly exposed to airborne
pollutants compared to low airborne pollutant exposed subjects
(108). In line with this finding, in a cohort of 81 individuals
aged 18-91, methylation levels of the mitochondria gene 12S
rRNA inversely correlated with age suggesting that mtDNA
methylation may represent an epigenetic marker of ageing
(109). In the retina of diabetic mice mtDNA methylation
was found associated with mtDNA damage characterized by
increased base mismatches and hypermethylated cytosines.
Interestingly, inhibition of DNA methylation, or regulation of
cytosine deamination, attenuated base mismatches at the D-loop
thus preventing mitochondrial dysfunction and microvascular
damage. In this study epigenetic signals of mtDNA were
driven by oxidative stress as overexpression of Sod2 was
able to prevent diabetes-induced D-loop hypermethylation and
increase in base mismatches (110). Of clinical relevance, retinal
microvasculature from human donors with diabetic retinopathy
presented similar increase in D-loop methylation and decrease
in mtDNA transcription (111). In another study, analysis
of mtDNA methylation by bisulfite sequencing in senescent
endothelial cells showed alteration in the methylation pattern of
several genes regulating mitochondrial function and metabolism
(112). Patients with cardiovascular disease display a significantly
higher mtDNA methylation of genes encoding for cytochrome c
oxidases (MT-CO1, MT-CO2, MT-CO3), tRNA leucine 1 (MT-
TL1) and (1.67%, P = 0.0001) as well as genes involved in
ATP synthesis (MT-ATP6 and MT-ATP8) (113). The latter study
suggests that mtDNA methylation could serve as non-invasive
and easy-to-obtain epigenetic biomarker and may be implicated
in the etiology of CVD (Figure 3).
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FIGURE 3 | Schematic showing the main epigenetic networks regulating mitochondrial functionality and cardiovascular disease. PGC1α, Peroxisome
proliferator-activated receptor gamma coactivator 1-alpha; NRF1, Nuclear respiratory factor 1; mtDNMT1, Mitochondrial DNA methyltransferase 1; MT-CO (1-3),
Cytochrome c oxidase subunit (I, II, III); MT-TL1, Mitochondrially encoded tRNA-Leu 1; MT-ATP (6, 8) Mitochondrially encoded ATP synthase membrane (subunit 6, 8);
FOXO1, Forkhead box O3; PPAR1a, Peroxisome proliferator-activated receptor 1 alpha; GPx, Glutathione peroxidase; ERRα, Estrogen-related receptor alpha; IDH3,
isocitrate dehydrogenase 3; Cyt-c, Cytochrome c; COXV, Cytochrome c oxidase subunit 5; MCAD, Medium-chain acyl-CoA dehydrogenase; CPT-1β, Carnitine
Palmitoyltransferase 1 beta; PDK4, Pyruvate dehydrogenase lipoamide kinase isozyme 4; Nampt, Nicotinamide phosphoribosyltransferase; NAD+, Nicotinamide
adenine dinucleotide; AceCS2, acetyl-CoA synthetase 2; AMPK, 5′ adenosine monophosphate-activated protein kinase; HAT1, Histone acetyltransferase 1; RBBP7,




Growing evidence indicates that PTMs of histones, mainly
at lysine and arginine residues, significantly affect chromatin
accessibility thus enabling cell-specific transcriptional programs
implicated in mitochondrial dysfunction and vascular disease
(Figure 3). Sirtuins are class III histone deacetylases (HDACs),
homologs of the yeast protein Silent Information Regulatory 2
(Sir2), a deacetylase involved in yeast metabolism and lifespan
(104). The sirtuin family of deacetylases include seven enzymes
differentially distributed throughout the cell: SIRT1 and SIRT2
which are mainly localized in both cytoplasmic and nuclear
compartments; SIRT3 SIRT4, and SIRT5, which are localized in
the mitochondria, and SIRT6 and SIRT7 which are located in the
cell nucleus (29, 114, 115). The deacetylation reaction catalysed
by sirtuins is NAD+-dependent, and leads to the formation ofO-
acetyl-ADP ribose (AADPR) which can be used as a donor group
in ADP-ribosylation reactions (116). In term of activity, all the
above-mentioned sirtuins display a deacetylase activity with the
exception of SIRT4 which is mostly an ADP-ribosyl transferase,
and SIRT6 which exhibits both activities (104).
Available evidence indicates that sirtuins act as pivotal
regulators of life span and life-extending effects of calorie
restriction (2). Among the different sirtuins, SIRT3 is particularly
active in the mitochondria, where it is responsible for the
deacetylation of the acetyl-CoA synthase enzyme (AceCS2)
(117, 118). Under appropriate nutritional conditions, AceCS2 is
completely inactivated upon acetylation at Lys-642, while it is
rapidly reactivated by SIRT3 deacetylation (117). Deacetylation
of AceCS2 by SIRT3 increases AceCS2 activity leading to
the formation of O-acetyl-ADP-ribose and nicotinamide (118),
important metabolites implicated in biosynthetic and regulatory
purposes (119). In line with these studies, genetic deletion
of SIRT3 in mice or gene downregulation as the result of
high fat diet feeding, are associated with early metabolic
abnormalities which are mainly the result of mitochondrial
dysfunction (120). SIRT3 also regulates mitochondrial oxidative
stress levels by deacetylation of the antioxidant enzyme MnSOD
(121). Although not localized in the mitochondria, SIRT1 is a
major regulator of mitochondrial function via deacetylation of
PGC1α and FOXOs proteins (122). SIRT1-mediated activation
of these target proteins leads to increased mitochondrial
respiration and lipid oxidation through regulation of several
genes (i.e., ERRα, IDH3, Cyt-c, COXV, MCAD, CPT-1β, and
PDK4) required in energy-depleted cell (29, 123). SIRT1 is also
critically involved in a dynamic cross-talk with AMPK, a key
molecular effector involved in cellular metabolism. Activation
of SIRT1/AMPK by physical activity or caloric restriction is
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associated with an increased usage of lipids as an energy source,
mitochondrial biogenesis as well as with an increased expression
of nicotinamide phosphoribosyl-transferase (Nampt), the rate-
limiting enzyme in NAD+ bio-synthesis. The increase in Nampt
activity leads to higher NAD+ production, which in turn
activates SIRT1 (124).
Of note, activation of AMPK by SIRT1 seems to be particularly
important for the phosphorylation of three main proteins
involved in epigenetic remodeling: the DNA methyltransferase
DNMT1, the histone acetyltransferase HAT1, and RBBP7,
which inhibits DNMT1 and is a HAT1 coactivator (125).
AMPK-mediated phosphorylation of these proteins triggered
nucleosome remodeling thus favoring the transcription of
nuclear-encoded genes involved in mitochondrial biogenesis
and function (125). These results show that SIRT1-AMPK
axis coordinates mitochondrial function with energy status
through epigenetic regulation of nuclear gene expression.
SIRT1 is also highly sensitive to the cellular redox state,
and confers cardioprotection by counteracting oxidative stress
through deacetylation of multiple cellular targets (126–128).
In the human endothelium, SIRT1 antagonizes H2O2-induced
premature senescence through its negative modulation of
p53 by deacetylation of Lys-373, Lys-382, and Lys-320 (129).
Conversely, endothelial SIRT1 overexpression reversed oxidative
stress-induced premature senescence through activation of
endothelial nitric oxide synthase (eNOS) (130). SIRT1 has
also shown to deacetylate FOXO3 thus preventing cellular
apoptosis via a mechanism involving the tumor suppressor
p53 (131, 132). On the other hand, ROS-dependent acetylation
of FOXO1 inhibits its transcriptional activity on SIRT1,
catalase (CAT), and MnSOD target genes thus creating a
detrimental vicious cycle driven by oxidative stress (133).
This molecular circuitry is reinforced by the activation of
the mitochondrial adaptor p66Shc which further amplifies
ROS levels (134). Interestingly, SIRT1 controls mitochondrial
oxidative stress by regulating the transcription of p66Shc (135–
137). SIRT1-dependent deacetylation of histone 3 reduces
chromatin accessibility on p66Shc promoter thus impeding
transcription. By contrast, SIRT1 downregulation as the results
of cardiovascular risk factors induces an open chromatin
eventually leading to p66Shc expression, mitochondrial oxidative
stress and endothelial dysfunction (138). It has also been
shown that SIRT1 overexpression increases mitochondrial
biogenesis and expression of antioxidant enzymes, namely
catalase and glutathione peroxidase (GPx), via activation of the
peroxisome proliferator-activated receptor coactivator (PPAR)
1-a activation (139).
SIRT5, a weak deacetylase with strong desuccinylase,
demalonylase, and deglutarylase activity, has been also
implicated in regulating different aspects of mitochondrial
metabolism and cardiovascular function (140). SIRT5
downregulation was recently associated with mitochondrial
dysfunction in endothelial progenitor cells of patients with
arterial hypertension (141). Other studies reported that
SIRT5 deficiency exert a protective role by suppressing
mitochondrial ATP production and promoting AMPK activation
in response to energy stress. Moreover, genetic deletion of SIRT5
protects against ischemic stroke via modulation of PI3K/Akt
pathway (142).
Recent evidence suggests that in the diseased aorta
containing atherosclerotic plaques and grafted arteriosclerosis,
REF1/H3K9me3 pathway is suppressed thus leading to an
increase in the mitochondrial translocation of the AIP1B isoform
with subsequent generation of mitochondrial ROS and EC
activation (143).
MITOCHONDRIAL ROS AND EPIGENETIC
CHANGES
Mitochondrial-generated ROS have a major impact on DNA
methylation. ROS can directly convert 5-methylcytosin (5mC)
to 5-hydroxymethylcytosine (5hmC) which blocks the activity
of DNMT1 leading to an improper methylation inheritance
during mitosis and global hypomethylation (144). Moreover
ROS can oxidize guanosine to 8-oxo-20-deoxyguanosine (8-
oxodG) thus inhibiting methylation of adjacent cytosine and
further contributing to global hypomethylation of DNA (145,
146). The formation of 8-oxodG in particular loci promotes the
transcription of pro-inflammatory genes in response to TNF-α
(147). Furthermore, 8-oxodG interacts with HIF1α thus affecting
its ability to bind VEGF promoter with subsequent impairment
of angiogenesis (148). In line with these observations, two
recent meta-analyses showed that high levels of 8-oxodG are
associated with atherosclerotic vascular disease and predict
outcome (149, 150). High ROS levels also influence both
repressive (H3K9me2/3 and H3K27me3) and active histone
marks (H3K4me2/3) (151, 152).
Similarly to DNA methylation, histone methylation is
dependent on SAM availability and is therefore reduced in
the presence of high ROS levels (153, 154). In support of
this hypothesis in a model of cardiac pressure overload the
SET and MYND domain containing protein 1 (SMYD1)
methyltransferase was significantly downregulated (155). On the
other hand, several studies showed that hyperglycemia-induced
oxidative stress increases the expression of the methyltransferase
SETD7 and its epigenetic marker H3K4m eventually leading to
enhanced transcription of inflammatory and oxidant genes, thus




By serving as essential cofactors for most chromatin-modifying
enzymes, important intermediates of cell metabolism and
dietary intake allow the integration of metabolic information
and transcriptional control (Figure 4). Fluctuating metabolite
concentrations are therefore proposed to provide signalling cues
for continual adjustment of gene expression by modulating the
epigenome to influence chromatin dynamics. Additional
biochemical evidence suggests that energy metabolite
concentration could affect PTMs of the chromatin-modifying
machinery itself, in turn regulating enzymatic activity,
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FIGURE 4 | Intermediate mitochondrial metabolites as cofactors for chromatin modifications. acetyl-CoA generated by glycolysis and β-oxidation acts as a substrate
for histone acetyltransferases (HATs). Nicotinamide adenine dinucleotide (NAD+) is required for histone deacetylases (HDACs; histone deacetylation) as well as
ADP-ribosyltransferases (ARTs). α-Ketoglutarate and flavin adenine dinucleotide (FAD+) are cofactors for DNA (ten-eleven translocations, TETs) and histone
demethylases [Jumonji C domain containing (JmjC), LSD1]. TCA, tricarboxylic acid cycle; HATs, histone acetyltransferases; NAD+, nicotinamide adenine dinucleotide;
HDACs, histone deacetylases; ARTs, ADP-ribosyltransferases; FAD, flavin adenine dinucleotide; TETs, ten-eleven translocations.
stability, and chromatin binding capacity associated with
gene expression (54).
NAD+
NAD+ is an essential cofactor for reactions catalysed by
the highly conserved SIRT HDAC family (2). Other NAD+
consuming enzymes such as ADP-ribosyltransferases have
also been shown to covalently ADP-ribosylate core histones
(157). PAR polymerases (PARPs) utilize NAD+ to catalyse
poly(ADPribose) synthesis and are involved in the cellular
stress response (158). Poly(ADP-ribose) polymerase-1 (PARP1),
a major member of the PARP family, is a nuclear protein
involved in chromatin remodeling and promotion of DNA
repair (159). However, several studies report that in condition
of oxidative stress PARP-1 also localizes to mitochondria (160–
162). Mitochondrial PARP-1 is reported to actively participate
in maintenance of functional integrity of the organelles (163)
and to play a detrimental role when hyperactivated (160,
164). Furthermore, the potential role of PARP1 as a nuclear
epigenetic regulator for the maintenance of mitochondrial
DNA integrity has been suggested (159). Indeed, PARP-1
suppression reduces mtDNA integrity, as well as the expression
of mitochondria-encoded respiratory complex subunits COX-
1, COX-2, and ND-2 (164). Accordingly, PARP-1 localizes
at promoters of nuclear genes encoding both the mtDNA
repair proteins UNG1, MYH1, and APE1 and the mtDNA
transcription factors TFB1M and TFB2M (164). Consistent with
these findings, PARP-1 suppression impairs mitochondrial ATP
production (164).
S-Adenosylmethionine
S-Adenosylmethionine (SAM) is produced by the condensation
of methionine and ATP during the first of nine steps required for
the conversion of methionine to succinyl-CoA, a predominantly
cytoplasmic pathway that ends up in the mitochondria (29).
It contains the active methyl-donor group utilized by most
methyltransferase enzymes. It has been demonstrated that ROS
can reduce SAM availability, thus limiting the activity of
DNA and histone methyltransferases (145). This is achieved
either by inhibiting methionine adenosyl-transferase and thus
SAM synthesis or by inhibiting methionine synthase and thus
methionine regeneration (56). Interestingly, long-term exposure
to H2O2 decreased SAM levels leading to hypomethylation of
the long interspersed nuclear element-1 (LINE-1) (165). LINE-1
hypomethylation as an indicator of global methylation status was
found in blood from patients with ischaemic heart disease and
stroke, and has been related to higher risk for these diseases (166).
FAD+
Derived from the vitamin riboflavin (vitamin B2),
mitochondrial-generated FAD functions as the prosthetic
group for certain oxidation–reduction enzymes (2). For example,
LSD1 demethylase is a FAD+-dependent enzyme capable
of demethylating H3K4me1/2 and H3K9me1/2 (167). LSD1
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activity is regulated by redox state and it is stimulated when
FAD is oxidized (168). LSD1, in turn, regulates mitochondrial
respiration and energy expenditure. Specifically, LSD1 binds
directly to genes such as PGC1α, PDK4, FATP1, and adipose
triacylglycerol lipase (ATGL), and represses their transcription
associated with loss of H3K4 methylation (169).
β-Hydroxybutyrate
The ketone body β-hydroxybutyrate (βOHB) modulates several
signalling pathways with implications for metabolic disease and
diabetes (170). Prolonged fasting, calorie restriction, strenuous
exercise, or ketogenic diets are conditions associated with
increases in serum concentrations β-OHB (171). Interestingly,
βOHB is an endogenous inhibitor of many NAD+-independent
HDACs (172). HDAC inhibition by βOHB might affect the
pathogenesis of type 2 diabetes in at least two ways: through
direct regulation of HDAC-dependent glucose metabolism, or
by promoting resistance to oxidative stress (170). For examples,
βOHB-mediated inhibition of HDAC1 and HDAC2 increases
acetylation of histone H3K9 and H3K14 and establishes a
permissive chromatin configuration for the expression of Foxo3
with subsequent transcription of its downstream antioxidant
genes such as catalase and MnSOD (172). Similarly, βOHB
may have similar effects on mitochondrial function, glucose
homeostasis, and obesity through endogenous inhibition of
HDAC3. The mechanism for these metabolic benefits of class
I HDAC inhibition may be the upregulation of PGC1α in a
variety of tissues (173, 174). Transcription of FGF21 is similarly
upregulated via βOHB-mediated inhibition of HDAC3 which
results in the activation of ketogenesis in obese mice (175).
The microvascular and macrovascular complications of type 2
diabetes are thought to be due in part to increased oxidative stress
brought on through several pathways including polyols, protein
kinase C, hexosamine, and advanced glycosylation end products
(176). In this context, the emerging role of βOHB in suppressing
oxidative stress may be relevant for the management of diabetic
complications. Other studies have previously suggested a role
for both βOHB and HDAC inhibitors in the protection from
oxidative or ischemic stress (170).
α-Ketoglutarate
Connections between metabolic cofactors and enzymes
associated with the removal of epigenetic methyl modifications
are also emerging (54). The TET family of dioxygenases
mediate the oxidation of 5mC. The potential for the TET family
(TET1/2/3) to regulate diverse physiological functions including
metabolic signalling requires the TCA cycle metabolite α-KG,
and this activity is inhibited by 2-hydroxyglutarate (2HG) (2)
(Figure 4). This means that oxygen deficiency and disturbances
in mitochondrial metabolism could affect the activation of TET
enzymes and thus control DNA methylation (177). Hearts of
mice exposed to high-fat diet (HFD) showed reduced levels of
αKG and this observation was paralleled by a compromised
TET1 function. Accordingly, an exogenous source of αKG
restored the DNA demethylation cycle, glucose uptake, and
insulin response (178).
Jumonji C domain-containing histone demethylases are
α-KG-dependent (177). Although studies are yet to determine
the TET-metabolism connection, mutations in isocitrate
dehydrogenase genes are associated with reduced α-KG and
elevated 2HG levels leading to genome-wide changes in histone
and DNA methylation patterns (54).
The Jumonji C domain (JmjC) containing lysine demethylases
(KDM) are the largest group, which can be divided to six
subgroups (KDM2-7) depending on their chromatin interacting
domains and substrate specificity (179). The activation of
these enzymes is also dependent on the presence of α-KG.
Therefore, disturbances in Krebs cycle function can affect histone
methylation and gene expression (177).
Acetyl-CoA
Acetyl-CoA generated from glucose and fatty acid metabolism
feeds into the TCA cycle to contribute to cellular energy
supply. Importantly, acetyl-CoA is the essential acetyl group
donor to lysine acetylation reactions and both pharmacological
and genetic interventions that modify cellular acetyl-CoA
concentrations directly affect acetylated proteins including
histones (180). Because histone acetylation is ubiquitously
associated with open chromatin and gene expression, acetyl-CoA
links intermediary carbon metabolism with chromatin dynamics
and transcription (54).
EPIGENETIC THERAPIES
Targeting epigenetic modifications is a highly promising
approach to restore gene expression and to rescue or prevent
mitochondrial insufficiency and vascular dysfunction. There are
several examples of how specific interventions can be employed
to modify the landscape of DNA/histone modifications in
this setting.
Studies in knockout mice have shown that class I HDACs
play a key role in regulating metabolism. Chronic treatment with
butyrate, a broad HDAC inhibitor that is expected to phenocopy
HDAC3 loss-of-function, prevents metabolic alterations in diet-
induced obese as well as in aged mice, mainly by enhancing
oxidative phosphorylation and beta-oxidation in mitochondria
(181, 182). Butyrate treatment also improves mitochondrial
biogenesis via epigenetic modulation of PGC-1α as well as
induction of several microRNAs such as miR-133a-3p, miR-208b,
and miR-499-5p, implicated in the regulation of mitochondrial
potential and integrity (183). Similarly, the class I HDAC
inhibitor SAHA, but not a class II HDAC inhibitor, increases the
expression of PGC-1α thus leading to enhanced mitochondrial
biogenesis, oxygen consumption in adipose tissue and skeletal
muscle from mice with type 2 diabetes (174). These changes
were associated with a significant improvement of insulin
sensitivity, metabolic rate and oxidative metabolism (174).
Moreover, treatment with SAHA was also found to reduce
ischemia-reperfusion injury following myocardial infarction
and to prevent apoptosis in cultured myocytes subjected to
hypoxia/reoxygenation (184, 185).
Pharmacological modulation of sirtuins has also shown to
impact on mitochondrial functionality and vascular function
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(186). Although primarily known as a nuclear protein, SIRT1-
mediated deacetylation of PGC-1α has been extensively
implicated in metabolic control and mitochondrial biogenesis,
which was proposed to partially underline SIRT1 role in caloric
restriction and impacts on longevity. Moreover, recent evidence
suggests that modulation of SIRT1 activity may also affect
the turnover of defective mitochondria by mitophagy (187).
In line with these evidences, SIRT1 activation by resveratrol
improves vascular function while attenuating dyslipidaemia
and obesity-induced metabolic alterations in human subjects
(188). SIRT1-dependent improvement of flow-mediated
dilation can be partially explained by increased deacetylation of
p66Shc promoter as well as posttranslational and transcriptional
regulation of endothelial NO synthase (eNOS) (137, 189). Indeed,
SIRT1 inhibition significantly increases p66Shc transcription,
mitochondrial oxidative stress and organelle disruption.
Whereas, in both the diabetic vasculature and myocardium
activation of SIRT1 suppresses p66Shc signalling thus preventing
the accumulation of H2O2 in mitochondria and cellular
death (137, 138, 190). Pharmacological activation of SIRT3
by small molecules, namely 7-hydroxy-3-(4′-methoxyphenyl)
coumarin (C12), also represents a promising approach to
prevent mitochondrial ROS via deacetylation and activation of
MnSOD (121).
Together with SIRT1, other epigenetic modulators participate
to the transcriptional regulation of the mitochondrial adaptor
p66Shc. Modulation of CpGDNAmethylation by folates regulates
p66Shc transcription (138). Consistently, a recent work found
that homocysteine stimulates p66Shc transcription in human
endothelial cells via specific CpG dinucleotides demethylation
in the p66Shc promoter (191). Of note, p66Shc promoter
CpG methylation was significantly reduced in peripheral blood
leukocytes of patients with coronary artery disease and high
plasma homocysteine levels, thus strengthening the relevance of
p66Shc-related epigenetic changes in the context of cardiovascular
disease (191). Moreover, metformin, a widely used antidiabetic
drug, was found to modulate SIRT1-p66Shc signaling in
experimental models of diabetes (138, 192, 193).
Inhibitors of histone acetyltransferases have also shown to
revert mitochondrial oxidative stress. The dietary compound
curcumin, an inhibitor of the histone acetyltransferase
CBP/p300, has shown to rescue hyperglycemia-induced
endothelial dysfunction by regulating the expression of several
pro-oxidant and antioxidant enzymes involved in mitochondrial
oxidative stress and mitochondrial biogenesis (194). Similarly,
inhibition of another acetyltransferase, GCN5, prevents
angiotensin II–mediated downregulation of catalase thus
fostering accumulation of mitochondrial ROS (195).
CONCLUSIONS
In conclusion, evidence discussed so far strongly suggests that
specific epigenetic signals are responsible for transcriptional
changes leading tomitochondrial dysfunction and cardiovascular
disease. In turn, the availability of mitochondrial intermediate
metabolites controls the activation of chromatin modifying
enzymes. The growing understanding of chromatin
modifications and their impact on transcription, will open
perspective for the development of personalized biomarkers
and epigenetic therapies aimed at preventing mitochondrial
dysfunction and cardiovascular disease.
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